Skip to main content
PlainMeds

Prescription medicine

Trastuzumab-dkst Brand names: Ogivri

Trastuzumab-dkst (Ogivri) is a prescription medicine with an FDA approval on record since 2017. No generic is listed in FDA's NDC Directory.

  • No generic listed

Check it at the source: trastuzumab-dkst labels on DailyMed; the BLA 761074 record on Drugs@FDA; every trastuzumab-dkst label on DailyMed.

Highlights of the record

no current FDA label; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026

Used for

The label in openFDA carries no indications section.

Forms and strengths

Kit.

On the market

Earliest approval on file
December 1, 2017 Ogivri, Mylan Gmbh; Drugs@FDA’s file, where older or withdrawn approvals can be missing
Generic approvals
No generic approved
Labelers listed (NDC)
1 of which 0 under generic applications, 1 under brand applications, repackagers included

Supply and safety

Pharmacy cost (NADAC)
Not in the survey
Shortage (FDA)
No current entry
Recalls by its makers (FDA)
No recall recorded
FAERS reports
261 through July 30, 2026

Is there a generic for trastuzumab-dkst (Ogivri)?

No generic trastuzumab-dkst is approved (Drugs@FDA, October 8, 2026).

  • 2017 earliest approval on file

Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)

What do FAERS reports show for trastuzumab-dkst?

The FDA Adverse Event Reporting System holds 261 reports that list trastuzumab-dkst among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 45 are coded as a death and 88 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.

The most reported reactions

  • Death (an outcome recorded in the report)30
  • Off Label Use (a use or a product term, not a reaction)28
  • Chills18
  • Back Pain17
  • Diarrhoea17
  • Disease Progression (a use or a product term, not a reaction)17
  • Dyspnoea16
  • Fatigue15

Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026

What next?

Other her2/neu receptor antagonists
the pharmacologic class, with prices and generics
Trastuzumab-dkst side effects
the label's list beside FAERS reports
Check an interaction
what two or more labels say about each other